2025-10-17 - Analysis Report
Okay, here's an analysis of Intuitive Surgical (ISRG) based on the data you provided.

**0. Report in English with Numerical Highlights and Analysis**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** ISRG
*   **Company:** Intuitive Surgical Inc. (A company that designs, manufactures, and markets robotic surgical systems.)
*   **ISRG Cumulative Return:** 62.57%
*   **VOO Cumulative Return:** 96.43%
*   **Absolute Divergence (Current):** -37.8%
*   **Relative Divergence:** 0.0 (Indicates ISRG's current divergence is at the lowest end of its historical range compared to VOO).

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha  | Beta  | Cap(B) |
|------------|---------|---------|--------|-------|--------|
| 2015-2017  | 68.0%   | 77.6%   | 40.0%  | -0.1  | 43.4   |
| 2016-2018  | 64.0%   | 72.2%   | 49.0%  | -0.0  | 57.0   |
| 2017-2019  | 54.0%   | 72.2%   | 31.0%  | 0.2   | 70.3   |
| 2018-2020  | -6.0%   | 80.4%   | -29.0% | 0.3   | 97.4   |
| 2019-2021  | 29.0%   | 80.4%   | -18.0% | 0.6   | 128.3  |
| 2020-2022  | -23.0%  | 80.4%   | -22.0% | 1.2   | 94.7   |
| 2021-2023  | -17.0%  | 77.5%   | -18.0% | 1.7   | 120.5  |
| 2022-2024  | 36.0%   | 77.5%   | 15.0%  | 1.7   | 186.3  |
| 2023-2025  | 25.0%   | 72.7%   | -36.0% | 0.8   | 155.8  |

**Analysis:**

*   **Underperformance:** ISRG has significantly underperformed the S&P 500 over the period analyzed, with a cumulative return difference of -37.8%. The relative divergence being at its minimum suggests this underperformance is at its most extreme point historically.
*   **Alpha and Beta:**  The Alpha values are generally negative in recent years, indicating underperformance relative to the market. The Beta values are generally positive, showing that the stock is sensitive to market movements.  The negative Alphas coupled with positive Betas suggest ISRG hasn't provided excess returns for the risk taken recently.
*   **CAGR and MDD:** While the CAGR (Compound Annual Growth Rate) shows strong growth in some periods, the MDD (Maximum Drawdown) indicates significant potential for loss.
*   **Capitalization:** Market Cap has been volatile and increased.

**2. Recent Price Action**

*   **Current Price:** 436.39
*   **Last Market Close:** Price: 434.62, Previous Close: 435.61, Change: -0.23
*   **5-Day Moving Average:** 436.56
*   **20-Day Moving Average:** 441.25
*   **60-Day Moving Average:** 462.72

**Analysis:**

*   **Downtrend:** The price is below both the 20-day and 60-day moving averages, suggesting a short-term and medium-term downtrend.
*   **Minor Price Drop:** The small price decrease at the last market close indicates a slight downward pressure.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommendation)
*   **RSI:** 45.39 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.0459 (Near zero suggests that the averages are close, indicating that the trend is weak or that the price is consolidating. )
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90)
*   **Recent (20-Day) Relative Divergence Change:** -1.2 (Short-term Decline)
*   **Expected Return:** 1292.6% (Long-term, relative to S&P 500)

**Analysis:**

*   **MRI:** A medium investment recommendation suggests that, based on the current risk environment, an investment is moderately advisable.
*   **RSI:** The RSI is close to 50, indicating no strong momentum in either direction.
*   **PPO:** PPO near zero indicates market sideways or in consolidation mode.
*   **Divergence Change:** The negative change in relative divergence confirms the short-term underperformance compared to the S&P 500.
*   **Expected Return:** The extremely high expected return should be viewed with caution. This likely stems from specific modeling assumptions and historical data and does not guarantee future performance.

**4. Recent News & Significant Events:**

*   **Bullish Sentiment (Insider Monkey):** Wall Street appears generally positive ahead of FQ3 2025 results.
*   **Alternative Investment Consideration (Motley Fool):** Suggests exploring other medical device stocks.
*   **Price Target Adjustment (MT Newswires):** Baird lowers its price target but maintains an "Outperform" rating.
*   **Ion's Potential (Zacks):** Focuses on Intuitive Surgical's growth opportunities in ambulatory care through its Ion platform.
*   **Key Considerations Before Buying (Motley Fool):** Provides insights for potential investors.
*   **Unstoppable Growth Stocks (Motley Fool):** ISRG is mentioned as a potential growth stock during market downturns.

**Analysis:**

*   **Mixed Signals:** The news presents a mixed picture. While some analysts remain bullish and highlight growth opportunities, others suggest considering alternatives and have adjusted price targets downwards.
*   **Focus on Growth:** The emphasis on Ion and ambulatory care suggests the market is looking at Intuitive Surgical's ability to expand into new areas.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.94)
*   **Target Price:** Avg: $568.40 / High: $685.00 / Low: $350.00
*   **Recent Rating Changes:** Not Available

**Analysis:**

*   **Positive Outlook:** The analyst consensus leans towards a "Buy" rating, suggesting optimism about the stock's future performance.
*   **Significant Price Target Range:** The wide range between the high and low target prices indicates uncertainty among analysts.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-07-23 | 1.84 | 2.44 B$    |
| 2025-04-23 | 1.95 | 2.25 B$    |
| 2024-10-18 | 1.59 | 2.04 B$    |
| 2024-07-19 | 1.48 | 2.01 B$    |
| 2025-07-23 | 1.48 | 2.01 B$    |

**Analysis:**

*   **Generally Positive:** Revenue and EPS have been generally increasing over the recent quarters.
*   **Latest Trend:** Although revenue increased in the latest quarter, EPS slightly decreased compared to the previous quarter.

**6. Financial Information**

Revenue and Profitability:

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $2.44B     | 66.31%        |
| 2025-03-31   | $2.25B     | 64.69%        |
| 2024-12-31   | $2.41B     | 68.04%        |
| 2024-09-30   | $2.04B     | 67.41%        |
| 2024-06-30   | $2.01B     | 68.30%        |

Capital and Profitability:

| Quarter      | Equity     | ROE     |
|--------------|------------|---------|
| 2025-06-30   | $17.85B    | 3.69%   |
| 2025-03-31   | $17.11B    | 4.08%   |
| 2024-12-31   | $16.43B    | 4.17%   |
| 2024-09-30   | $15.58B    | 3.63%   |
| 2024-06-30   | $14.71B    | 3.58%   |

**Analysis:**

*   **Revenue Growth:**  Intuitive Surgical has shown consistent revenue growth over the past several quarters.
*   **High Profit Margins:** The company maintains very high profit margins, indicating strong pricing power and efficient operations.
*   **Increasing Equity:**  Equity has been steadily increasing, reflecting retained earnings and balance sheet strength.
*   **ROE Fluctuation:** ROE (Return on Equity) has fluctuated, but remains at a healthy level, indicating good profitability relative to equity.

**7. 종합적인 분석 (Overall Analysis)**

*   **Underperformance & Recovery Potential:** ISRG has underperformed the S&P 500 recently, but analyst consensus and the long-term expected return suggest potential for future recovery. The expected return should be carefully considered with a grain of salt.
*   **Mixed Signals:** Analyst opinions and recent news present a mixed picture, with some bullish sentiment offset by price target reductions and alternative investment suggestions.
*   **Strong Fundamentals:** ISRG has a solid financial foundation with consistent revenue growth, high profit margins, and increasing equity.
*   **Growth Opportunities:** The focus on the Ion platform and ambulatory care suggests the company is actively pursuing growth opportunities in new markets.
*   **Technical Downtrend:** The stock is currently in a short-term downtrend, but the RSI is neutral.
*   **Investment Recommendation:** MRI suggests a Medium Investment, but investors should carefully weigh the underperformance, mixed signals, and potential growth opportunities before making a decision.

**In summary, Intuitive Surgical is a fundamentally strong company with growth potential, but it has faced recent underperformance and presents a mixed picture in terms of analyst sentiment and technical indicators. A long-term investment perspective, considering the potential for recovery and expansion into new markets, is warranted.**
